WeVote
Log In

Bill

Bill

SB 256

relative to the affordability and safety of clinician administered drugs.

2025 Regular Session Introduced by Bill Gannon and 3 co-sponsors

New Hampshire bill regulates clinician-administered drug affordability and safety standards to improve access and clinical oversight.

Committee Report: Ought to Pass with Amendment # 2025-3029s, 01/07/2026; Vote 5-0; CC;
0
WeVote Research Nonpartisan
Bill Summary · SB 256

Legislative bill overview

SB 256 addresses the affordability and safety of drugs administered by clinicians in New Hampshire. The bill has been referred through committee review processes with amendments proposed to modify its original language. The legislation appears designed to regulate or improve oversight of clinician-administered pharmaceutical services.

Why is this important

Clinician-administered drugs—medications delivered directly by healthcare providers rather than dispensed to patients—represent a significant healthcare cost and safety concern. This bill could affect drug pricing transparency, patient access to treatments, and clinical safety standards across New Hampshire's healthcare system.

Potential points of contention

  • Drug pricing mechanisms: Whether the bill adequately addresses cost controls without disrupting market competition or provider reimbursement models
  • Implementation burden: Regulatory requirements for clinicians and healthcare facilities to comply with new safety or affordability standards
  • Scope of drugs covered: Disagreement over which administered drugs fall under the bill's requirements and whether exemptions are appropriate for specialty pharmaceuticals

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.